ArticleDiscover oncology2025
Antibody-drug conjugates in triple-negative breast cancer (2010-2024): a bibliometric analysis of global trends and clinical translation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Knowledge mapping of alström syndrome research: a bibliometric and visualization analysis based on WoS data from 2000 to 2025.Frontiers in genetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTriple-negative breast cancer (TNBC) is an aggressive subtype with poor outcomes. Antibody-drug conjugates (ADCs), linking monoclonal antibodies to cytotoxic payloads, show promise as targeted therapies. Despite growing interest, bibliometric studies on ADCs in TNBC are limited. This study aims to fill this gap by identifying key research trends, emerging areas, and clinical applications within the field of ADCs in TNBC.
methodsA comprehensive search of 492 publications on ADCs for TNBC, published between 2010 and 2024, was conducted using the Web of Science Core Collection. Bibliometric analysis was performed using CiteSpace, VOSviewer, and Bibliometrix, and core journals were identified via Bradford's Law.
resultsThe analysis revealed a continuous and steady increase in the number of articles published in this field over the past decade. Significant advancements in this field have been achieved by the United States, with Harvard Medical School being the most prolific institution, publishing 40 papers. Dr. A. Bardia from the United States was identified as the leading author, with 28 articles. The journal "Cancer Research" emerged as the most cited publication. By utilizing keyword co-occurrence and clustering analyses, current studies have pinpointed treatment strategies and diseases prognosis as key areas of focus. The dual-map overlay of journals indicates a gradual shift in research trends from biochemistry and genetic studies to immunology and clinical research. The development of next-generation ADCs (e.g., Dato-DXd, SKB264) holds the potential to transform TNBC therapeutics, particularly for tumors with heterogeneous target expression.
conclusionThis study provides valuable insights into the current research status, recent advancements, and emerging trends in ADCs for TNBC, offering data support for the precise classification and treatment of TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.